A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients

Trial Profile

A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Detrusor instability; Neurogenic bladder
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 19 Apr 2018 Planned primary completion date changed from 12 Jun 2020 to 9 Mar 2020.
    • 17 Oct 2017 Planned End Date changed from 1 Mar 2020 to 12 Jun 2020.
    • 17 Oct 2017 Planned primary completion date changed from 1 Mar 2020 to 12 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top